biotech sector

Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious diseases, including COVID-19, influenza, respiratory syncytial and Ebola. Its shares ran up to $331.68 on Feb. 9, 2021, on its COVID-19 vaccine,...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Precision BioSciences Shares Jump On Gene Editing Pact With Novartis Precision BioSciences Inc (NASDAQ: DTIL) has entered into an exclusive worldwide in vivo gene editing research and...

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week. BeyondSpring Inc. (NASDAQ: BYSI) was...

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal Reserve's monetary policy setting arm — the FOMC — met this week and the key takeaway from...

Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE) shares came...

Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns. Several big-name pharma companies, including Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE), reported earnings during the week....

Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp. (NYSE: PANA) and South Mountain Merger Corp. (NASDAQ: SMMC) each announced business combination...

Biotech stocks advanced along with the broader market in the week ended Oct. 9, although the news flow was quite light. Antibody treatment for COVID-19 took the spotlight during the week, with both Eli Lilly And Co (NYSE: LLY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) requesting for...

Biotech stocks made a steady recovery over the week ended Oct. 2, although Friday's weakness trimmed some of the gains of the week. Companies working on anti-COVID-19 antibody treatments were in the news during the week. Sorrento Therapeutics Inc. (NASDAQ: SRNE) announced a second more...

Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves. A big-ticket M&A was announced at the start of the week. Gilead Sciences Inc. (NASDAQ:...

Novavax Inc. (NASDAQ: NVAX) announced on Monday it had started the first phase of its novel coronavirus (COVID-19) vaccine trials. What Happened The pharmaceutical company said it had enrolled the first participants for the testing of the "NVX‑CoV2373" vaccine, and the...

Moderna Inc. (NASDAQ: MRNA) announced Monday it is planning to raise more than $1.3 billion in a secondary public offering. What Happened The biotechnology company said it is offering 17.6 million common shares priced at $76 each. Underwriters will have an option to purchase an additional 2.64...

Drug developer Osmotica Pharmaceuticals is expected to begin trading Thursday on the Nasdaq Global Market under the ticker symbol “OSMT.” The Details Over 60 percent of Osmotica's total revenues in 2017 and 80 percent of the first half of 2018 were produced by the sales of generic...

Between late-stage readouts and regulatory events, the biotech industry has enough second-half catalysts to potentially actualize Cantor Fitzgerald’s investment theses and justify its price targets, according to the firm’s recent note. The most imminent is Versartis Inc (NASDAQ: VSAR)...

The biotech sector has seen better times this year after the disappointing showing in 2016. Calithera Biosciences Inc (NASDAQ: CALA) has been a stand-out performer in the sector, clocking gains in excess of 300 percent in the year-to-date period. But, does it qualify for the tag "best-in-...